Investigational targeted oral peptide JNJ-2113 demonstrated positive results in moderate-to-severe plaque psoriasis in Phase 2b study published in New England Journal of Medicine

/PRNewswire/ -- Johnson & Johnson today announced publication in the New England Journal of Medicine (NEJM) of the Phase 2b FRONTIER 1 trial results for...

Related Keywords

Canada ,Spring House ,British Columbia ,Montreal ,Quebec ,United States ,Americans ,Prnewswire Johnson ,Craig Stoltz ,Robert Bissonnette ,Lloyd Miller ,Thompson Jr ,Exchange Commission ,Innovaderm Research ,Janssen Research Development ,National Psoriasis Foundation ,Everyday Health ,Johnson Inc ,Protagonist Therapeutics Inc ,Neither Janssen Research Development ,Janssen Biotech Inc ,Johnson ,Johnson Company ,New England Journal ,Psoriasis Area ,Severity Index ,Chief Executive Officer ,Medical Director ,Patient Reported Outcomes ,Psoriasis Symptoms ,Signs Diary ,Dermatology Life Quality Index ,Vice President ,Immunodermatology Disease Area Leader ,Protagonist Therapeutics ,Janssen Biotech ,Global Assessment ,Body Surface Area ,Plaque Psoriasis ,Innovative Medicine ,Private Securities Litigation Reform Act ,Janssen Research ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Neither Janssen Research ,Allergy Clin Immunol ,Accessed February ,Accessed January ,Life Quality Index ,Serum Samples ,Inflammatory Bowel ,Johnson Amp ,